KCT0008332
Recruiting
未知
A phase II study for the evaluation of the feasibility of lazertinib 160 mg per day in patients with EGFR T790M mutant non-small cell lung cancer
ConditionsNeoplasms
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Samsung Medical Center
- Enrollment
- 117
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\[Inclusion Criteria]
- •(1\) Pathologically diagnosed non\-small cell lung cancer.
- •(2\) Patients with advanced stage lung cancer that cannot be curatively treated with surgery or radiotherapy and require palliative therapy.
- •(3\) Patients who are EGFR mutation positive and have developed resistance to at least one agent, including first\-generation EGFR inhibitors (gefitinib, erlotinib) or second\-generation inhibitors (afatinib, dacomitinib), while taking or after taking at least one agent, and subsequent genetic testing (PCR test or NGS test) of blood or lung cancer tissue confirms the EGFR T790M resistance gene.
- •(4\) Are able to take the study drug (lazertinib) by mouth or through a Levin tube.
- •(5\) Capable of making an informed decision to participate in this study
- •(6\) 19 years of age or older
- •(7\) ECOG 0\-2
- •(8\) Minimum life expectancy of 12 weeks
- •(9\) Adequate organ function
Exclusion Criteria
- •\[Exclusion Criteria].
- •(1\) Subjects who have previously developed resistance after taking a third\-generation EGFR tyrosine kinase inhibitor (such as osimertinib). However, those who are unable to take osimertinib due to intolerable side effects of osimertinib prior to the development of resistance after taking osimertinib, etc. and need to take lazertinib as an alternative to osimertinib are eligible.
- •(2\) In the judgment of the physician, participation in this study would cause more harm than good to the patient: No specifics.
- •(3\) Uncontrolled central nervous system metastases.
- •\- Patients with asymptomatic brain metastases or investigator\-assessed CNS symptoms that are curable with an EGFR\-TKI may be enrolled.
- •(4\) Uncontrolled systemic disease, including uncontrolled hypertension, active bleeding, or active infection.
- •(5\) Therapy with radiation from a large field of irradiation within 1 week or therapy with radiation from a limited field of irradiation for palliative purposes within 1 week (local radiation therapy or gamma knife surgery).
- •(6\) Symptoms not relieved by prior therapy, \> CTCAE grade 1\.
- •(7\) Pregnant and lactating women.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Investigation on the role of ultra fractioned low dose radiation and chemotherapy in lower part (neck) of the wombHealth Condition 1: null- Women with histologically proven diagnosis of squamous cell carcinoma cervix FIGO stage IIB to IIIB will be included in the study.CTRI/2012/01/002358Fluid Research Grant CMC Vellore20
Not yet recruiting
Not Applicable
A Phase II Single-Arm Study to Evaluate the Feasibility of Preoperative Rehabilitation and Nutrition Intervention in Patients Undergoing Resection for Hepato-Pancreato-Biliary Surgeries.HBP malignancies (major hepatectomy, pancreatoduodenectomy)JPRN-UMIN000048073Keio University60
Recruiting
Not Applicable
A Phase II Single-Arm Study to Evaluate the Feasibility of Preoperative Rehabilitation and Nutrition Intervention in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Canceresophageal cancerJPRN-UMIN000045479Keio University33
Not yet recruiting
Phase 2
Feasibility of ISRT after chemo-immmunotherapy in early nodal DLBCHealth Condition 1: null- Newly diagnosed biopsy proven stage I-II nodal diffuse large B-cell lymphomaCTRI/2018/03/012340All India Institute of Medical Sciences
Recruiting
Phase 2
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLlymphoma10025320NL-OMON36830HOVO60